皮膚疾患における炎症に関与するサイトカイン産生細胞および線維化に関わる遺伝子発現についての研究
123
0
0
全文
(2) !)
(3) +
(4) %( '&+
(5) *. #$. ".
(6) ʜɂ ƿ̣ ʶ
(7) ʵ òʗʒƅ͏jp #
(8) j # ͨǛˉ˦gȷ̘
(9)
(10)
(11) ˔̖
(12)
(13) ƛΈȫȔjȗɓ
(14)
(15) ʛ˯ȷĉ
(16) ƛΈȗɓj̜́
(17)
(18) ¤·À«ÆØÐʄg}ʣʲ̗ʈ
(19) ÌÂʛ˯ˋ˙kˉ˦ŏͳ
(20) A)+')
(21) ˉ˦LjǤƔʚȷ̘
(22) (E1>D9 5>5K <?G)% ̔ȭ
(23) *̔ȭ
(24) ˏ̗Ɣʚ̔ȭ
(25) ƛΈǪ˗
(26)
(27) òʗʒƅ͏kŰŘu}ʛ˯Ĥʏˉ˦ɸǔ
(28) òʗʒƅ͏jp #
(29) j # ͨǛˉ˦
(30) Ø·Âˉ˦jgͨǛf³£Â©£äȷ̘ Ø·Âˉ˦ + ˉ˦jp # j #
(31) =)% ƚ͔̔ȭ ¤·À«ÆØÐdzDzǛʒƅ͏jp #
(32) ͨǛˉ˦ ˟ƣ ʶ ʵ ¡ÂÎæǛʛ˯ɬʒƅ͏jp #a j #a
(33) ͨǛˉ˦g ȷ̘
(34) ˔̖ . F.
(35) ƛΈȫȔjȗɓ
(36) ʛ˯ȷĉ ƛΈȗɓj̜́
(37) ÌÂʛ˯ˋ˙kˉ˦ŏͳ ÌẪɜîǒʀǛˉ˦ˀ̉ żΆĸɩ ˉ˦LjǤƔʚȷ̘ *̔ȭ ˏ̗Ɣʚ̔ȭ ƛΈǪ˗
(38) ¡ÂÎæǛʛ˯ɬʒƅ͏ɚɨlʥt} + ˉ˦ȷ̘ ¡ÂÎæǛʛ˯ɬǝˠ̃ɜîjp + ˉ˦ȷ̘ ¡ÂÎæǛʛ˯ɬʒƅ͏ɚɨlʥt} # ȷ̘ ¡ÂÎæǛʛ˯ɬǝˠ̃ɜîjp # ȷ̘ ¡ÂÎæǛʛ˯ɬʒƅ͏jp 3U)]ˉ˦ȷı ¡ÂÎæǛʛ˯ɬʒƅ͏jpƌƀŽɾjØ·Âˉ˦ȷı ¡ÂÎæǛʛ˯ɬǝˠ̃ɜîjpƌƀŽɾ
(39) ¡ÂÎæǛʛ˯ɬʒƅ͏jpƌƀŽɾj # ʞ͟ ¡ÂÎæǛʛ˯ɬǝˠjp̃ɟ 7 j +8 ˉ˦ʞ͟
(40) ¡ÂÎæǛʛ˯ɬʛ˯ʒƅ͏jp + ˉ˦³£Â©£äͨǛɼ ȷ̘
(41)
(42) ¡ÂÎæǛʛ˯ɬʛ˯ʒƅ͏jpƌƀŽɾ³£Â©£äͨǛ ɼȷ̘
(43) ̃ɜîǒʀǛˉ˦jp +8 ³£Â©£äͨǛˉ˦
(44) ¡ÂÎæǛʛ˯ɬjp # ͨǛØ·Âˉ˦ ˟ƣ . G.
(45) ʶ ʵ Ȗ}ؤ·DžʛʓÜÁáċǪjɑʖ́ljͺ
(46) ˔̖ ƛΈȫȔjȗɓ
(47) ؤ·ÜÁá ƛΈȗɓ
(48) Â×£»Ûßæº. ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁá . ½ÍªÂßäDZë ÌÃ㫵Ñãàä̔ȭ Ĥʏˋ˙ŊƔʚȷȱΒØ¿»äÂàãæÚȰ˹Γ A)+') ˏ̗Ɣʚ̔ȭ
(49) ƛΈǪ˗
(50) Â×£»Ûßæº. ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁájpʛ. ˯ˋ˙˕ˑŊ Â×£»Ûßæº. ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁájpˤ. ˋ˙˕ˑŊ Â×£»Ûßæº. ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁáʛ˯ˋ˙. jpˉ˦ƆŽ̭͂͟w͍ĄƑ =)% ʘɽ Â×£»Ûßæº. ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁáʛ˯ˋ˙. jp̃ʼͮƞj˕ˑŊ͂͟w͍ĄƑ =)% ʘɽ Â×£»Ûßæº. ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁáʛ˯ˋ˙. jp̴Ĭ̢ʽűƑ =)% ʘɽ Â×£»Ûßæº. ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁáʛ˯ˋ˙. jp˕ˑŊ͂͟w͍ĄƑ =)% ʘɽ Â×£»Ûßæº. ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁájpʛ. ˯˕ˑŊŖw½ÍªÂßäljͺ . H.
(51) Â×£»Ûßæº. ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁájpˉ. ˦ƆŽ̭͂͟w͍ĄƑ =)% ʘɽŖw½ÍªÂßäljͺ Â×£»Ûßæº ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁájp̃ ʼͮƞj˕ˑŊ͂͟w͍ĄƑ =)% ʘɽŖw½ÍªÂßäljͺ
(52) Â×£»Ûßæº. ̪˻Ⱦɹˉ˦ؤ·DžʛʓÜÁájp. ˕ˑŊ͟ëw͍ĄƑ =)% ʘɽŖw½ÍªÂßäljͺ ˟ƣ ˓Ƿjˍ̣
(53) ̷̥ ʋ̠ç̐ ŕ˟Ȓɺ . . I.
(54) ƿ̣ ʛ˯ĉ̆ͷʂĉ͢ǐɀ˧jǧ͓ůƙfbɷɿʚbŊƔʚj ʂɷʚƆʚ̌űk̳ƕgcʛ˯̆ʛbʟʛjʛéˋ˙ ưȺǪtjb̆ʛ ʟʛƁʉͷŽǀ˰lƓŶugct bƆưć˛w̆ʛéŽǀưbȦȶưbʿưj̓ư ư kbʟʛék˒ɹưñéưbñư ưkȺǪtg
(55) c ̆ʛƈ͏IJǪɳwǎğư ʫ̄w¯ß¾È³£Â̆ʛ̓Ŋˉ ˦ȺǪtjbʌˉ˦LjǤjṶ̈̀ťu}¯ß¾È³£Âͪ ưȺ́ǸcüÛÜàæˉ˦ͮƞǛ +ΒÛÜàæ ͨǛ +ΔÛÜàæ+3Γ ˉ˦bßä°áÉä·ˉ˦ bÛßÅäˉ˦̆ʛȾɹˉ˦lƓŶuj
(56) b̆ ʛʛ˯jpɎIJĕǸƆkʒœ˼j¡âá°äɷ̭Ēĥ͢o è͓̌ğmug c çȗbʟʛ{ƈ͏IJl˕ˑ̭kȺǪtgṶ̈̀èb̆ʛɊuļǛ jdžǛġgcʟʛ˒ɹươ˕ˑǪIJkǪDžˍŞ˙ ubǬd̃ʼʨˌl̰̄ugcñưjñéưʍˍŞ ˙kb{ͬ͞î˨ʼʨˌbˉ˦ǪIJƢgcʟʛ}Ƈn ˉ˦Ȧujb˴ɱàäËˉ˦9>>1D5<I=@8?9435<<Δ #bÛÜàæ ÒáËæ+ΒÛÜàæ ͨǛ +ΔÛÜàæ+8Γˉ˦ɻǏĤʏ͟ëw +8 +3 ˉ˦bST+ ˉ˦Βïؤ·ΓbØ·Âˉ˦b̭͞ˉ˦jDzœȁʥˉ˦ ƇȻˉ˦˝kǪʴg
(57) c òʗ¡ÂÎæǛʛ˯ɬbDžʛʓĤʏʌƻąhǥǛʚʛ˯ʑǝb ˴ɱĤʏˉ˦jɻǏĤʏˉ˦ɚɨlcòʗj¡ÂÎæǛʛ˯ ɬȦʒɼlΌnb̆ʛ¯ß¾È³£ÂIJŊ̢ʽʌƻɸǔ u}ɬʓǛʛ˯. J.
(58) ʑǝf cçȗbDžʛʓʬʑǝfbʟʛjg˕ˑŊĢʴɬʓ lʂv˴ƷĤʏʛ˯ʑǝfcʛ˯ĉ̆ͷ̍gůƙfbĒ ̋ąhʛ˯ʑǝ̎}ʜljͺëi}b̳ĉʚ~pnǕɿʧăʚ· Ââ·ǝˠëic{|ʑǝ͓ʓǁ Ǖɿʚǧʞ͟w r lžŦtjbwʂɖ̭(E1<9DI?6<965(&#͟ nc{ȍbʛ˯ʑǝœű̔ȝɑʖɓʤʴjȊŮʛ˯ʑ ǝǝˠ (&# šè}ǖ̌êŜɁf ˟ic òʗʛ˯͟ʽljͺŖwɬʓǛʑǝfbʛ˯ƤwƆ͏k ĸɩ}ʛ˯¤£á·ǣȰlǃm͕ bʛ˯ĤʏǗʹlɖǛŊt r ʘʓw
(59) ˟igc}bç͏òʗǝˠjgħ͍̿ ĄƑǂƅʌl}͍ĄƑlœűʘʓw
(60) ˟igcu kulb̝ugʘʓɀƿ̔ȝtjxbœűȨ~êȝfcòʗ jgbɖǛŊu}ʛ˯Ĥʏˉ˦¯ß¾È³£ÂDz˼ÔѾÃʃʂ÷̈́ tycɂgbʃʂt}Dz˼ÔѾÃ˴Ʒ % ȕɶ ̊ŞĉLjǪub ʛ˯Ĥʏˉ˦tɖǛŊty
(61) c{ˍȮbrhuʂv}Ǹːʚ ĤʏʌƻǥǛʚɬʓj¯ß¾È³£ÂIJŊ̢ʽɀ˧ʌƻ}u
(62)
(63)
(64). bòʗĨŸʚʓɹʂvtycwbƁʉlΎȝfʛ˯. ̱ͩu}˄ȓąhŒg͘ʙ˹ΏƮ̍}ʛʐlʂvr cò ʗǝˠŞČʓąhſŞlƇnbǕ̃ʼʑǝˢɤbˁƬʒà·lΌ g~pnƥũlʢnĞšlfcròʗɑʖbˌΈĺŽ g} ,- ɲƧͶɸʌʚȗɓ̄m}}bòʗʒǤ͟ˉ ˦n̔ȭtgk}cçȗbòʗʒƅ͏Ʉƻʛ˯ɊuƇn + ˉ˦lɚɨujb+ ˉ˦Ċk͟ëlʎg}c{rb+ ˉ˦¼ æ°¿Âu}ɑʖl̄b{˳ƾʚ˸ƌǪ˗ŘˍȮ }cwbòʗï + ˉ˦̱űwʒǤf ̞̦t}cɽŶbɖ ǛŊt} + ˉ˦ʆȬɷ̭l¯ß¾È³£ÂIJŊ̢ȑʌƻǃm̱rwr K.
(65) bòʗʒǤʂvty žŦtg
(66)
(67) c+ ˉ˦ˉ˦ͮƞǛˉ˦f +3 ˉ˦jĤʏ̢ȑ͟ëw +8 ˉ˦IJplbt +8 ˉ˦ ˉ˦ǛĤʏɖǛ͟ +8
(68) ˉ˦jɜǛĤʏ͟ëw +8 ˉ˦ ³Ð¹¿ÂIJ΄mcÿĻb+8 ˉ˦r kȺǪt ˟i g}}bòʗ +8
(69) ˉ˦̱űwʑǝf ˟ig}cuku lb Ƽ #
(70) # ɬʓ̟ƩǛ³£Â©£äʃʂw +8
(71) ˉ ˦ʘ̎
(72) ÿͤbòʗjg +8
(73) ˉ˦ľ͓fr lȝk }cɽ Ŷbòʗʛ˯ʑǝîȥʒǤ۩ŸÚ̔ȝl̈́gʑǝ
(74) bƇnIJƑȼʚ́lèƸtgc #a +8
(75) ˉ˦ˌ̲lʒǤÛ© ŸÚjǧ͓fr lʤ̞tglb+8
(76) ˉ˦kʃʂt #
(77) ǰķw~pōIJg
(78)
(79) }btʒǤ۩ŸÚ̔ȝl ɏc ¡ÂÎæǛʛ˯ɬ}͍ĄʚjĤʏƔʚ۩ŸÚl͟ëwǥǛɬʓ ǛʑǝfbɖǛŊt} + ˉ˦ʆȬɷ̭l¯ß¾È³£ÂIJŊ̢ȑʌƻ ʂvtyr lȝk g
(80) cĻ̺̿bòʗ #a +8
(81) ˉ˦ ˌ̲ɖǛŊlɸǔflbçȗb¡ÂÎæǛʛ˯ɬȻdĤʏˉ˦ ŗǗ˂̲lɖǛŊugc{}ɸƚˌ̲ȼʚ wIJƑȼʚ́ǽ ˇlųʹf}lbɽŶɑΈjg #)Qȼʚ u}IJƑȼʚ́l¡ÂÎ æǛʛ˯ɬņȮʚf
(82)
(83) žŦtjb̸ghèƸt óǠt c¡ÂÎæǛʛ˯ɬjg #)Qċʄw³£Â©£äf #a j #
(84) ʃʂl÷̈́ujbr ŸĤʏǗʹ͟ëw³£Â©£ä ¯ß¾È³£ÂɄƻIJŊǰķubʛ˯Êà¡ɀ˧Ĉétyr lž Ŧtg
(85) cçȗbòʗjǧ͓³£Â©£äfb¯ß¾È³£ Âɀ˧̢ʽ͟ëug # ŠȻċʄʥw.
(86) . r lžŦtjb. ¡ÂÎæǛʛ˯ɬjg # ʃʂ¡ÂÎæǛʛ˯ɬʒǤLjǪ͟ëu g
(87) r lȝk gcwb¡ÂÎæǛʛ˯ɬjg¯ß¾ L.
(88) ȳ£ÂơͪưȺ́ȺǪwè͓̌Ϣ߮àäãààä ¼äḘ̈lr³£Â©£äǰķtbÊà¡ɀ˧ˑǸ͓̌ f¯ß¾È³£ÂɄƻIJŊlųʹ r lȝk g
(89) c Ϣ߮àä¯ß¾È³£Â¯ß¾ä˕ˑįͰwċʄǸbãàà ä¯ß¾È³£Â̓Ŋͭwˉ˦˰ï̌ȺǪ̌ˆfħ¯ß¾È ³£Â̓Ŋǖ̌êŜɁfc}b̓Ŋu}¯ß¾È³£ÂɎIJĕǸ ͟ƉɱĕɣűƑϢ߮àäʆȬfbϢ߮àä̆ʛjpɎ IJˑǸ͓̌fcńib¡ÂÎæǛʛ˯ɬbuuϢ߮àä ͍ĄƑƅʌl̞b¡ÂÎæǛʛ˯ɬjgɸǔʚ¡ÂÎæǛ ʛ˯ɬʒǤfÊà¡ɀ˧Ĉé
(90)
(91) ʂvty̌űlgnʂvg r lʤ̞tgc{ˍȮbʂv}ʛ˯Êà¡ɀ˧Ĉéb¡âá° äjǓʂɷȡ͵ƟȞtyb¡ÂÎæǛʛ˯ɬǝˠ + ˉ˦³Ð¹ ¿Â +8 ˉ˦ġćĞpgc+8 ˉ˦̴ĬűƑf +29>49>7 @B?D59>Β +Γ{IJŊlķǐtbè̺u}hɜǛĤʏ͟ ëujb ˉ˦kLj̭ˉ˦IJŊƩnr Dzĉʃʂ͟ëugc DzĉȐʮ΄¼£ÑlƓŶwlbʛ˯kĒĥu}DzœƤwĤʏǗʹ ͓̌fDzĉ 7 fcƛͭb 7 ¡âá¬æŗǗ ͟ēlfr lʡ gc¡ÂÎæǛʛ˯ɬjgb 7 ŚƟĉf 3U)]ʘɽu gØ·Âˉ˦
(92) jƌƀŽɾ
(93) ɚɨlžŦtjbDzœ ˍŞu} 7 ȯȿLjǪØ·Âˉ˦jƌƀŽɾɖǛŊǃm̱rubŊƔĄ͉ɷ ̭ûu}¡âá¬æǛɬʓŗǗʂvtycwb+8 +8 ˉ˦~p nØ·Âˉ˦ƌƀŽɾ˴ɱĤʏˉ˦¡ÂÎæǛʛ˯ɬjp ŸĤʏǗʹ͟ëugc¡ÂÎæǛʛ˯ɬ #X j #
(94) ʃʂw +8 ˉ˦ # ʃʂw +8 ˉ˦ïĉ¡âá¬æǛʑǝ ˟i g lbçȗb¡ÂÎæǛʛ˯ɬʒǤLjǪ͓̌͟ɬʓǛŗǗ˴ ɱĤʏˉ˦ƇnĤʏˉ˦ʂvg ˟ig
(95) c. M.
(96) Džʛʓʛ˯~pnˤɛŊůƙ˕ˑŊw˴ƷĤʏʑǝflb Ȼdˉ˦lʒǤLjǪ͟ëujb̝ugʒǤ۩ŸÚlȝk ggcDžʛʓ˘Dz¹äÂãÛ¡DzĉbDzÂ×£»ÛßæºΕDzĉbDz ,
(97) )%' DzĉbDz )% ×àÛßæºDzĉ˴ƷDzĉlȷıtbɋˉ̃ʼɛƊ žŦtg
(98) cɽŶbDžʛʓͥƭǛDžʛʓ ɐʘǛDžʛʓ ƈĶwr lmcͥƭǛDžʛʓDz¹äÂãÛ¡DzĉlͨǛfb̃ ʼͮƞj˖k̈́̄ɸǔ wcçȗbɐʘǛDžʛʓDzÂ×£»Ûß æºΕDzĉDz )% ×àÛßæºDzĉlȷıtbɬʓǛk̈́̄Ǜʛ˯˕ˑ Ŋɸǔ wcɐʘǛDžʛʓ ͟ēlf̭͞Ǜˤɬbˤ̭͞ˉ˦˕ˑŊ ąhʑǝfbɆ}wœű cDžʛʓ˕ˑŊĢʴɬʓ h˵ɆǛΌg˴ƷĤʏʑǝfbʘʓ۩ŸÚêȝͶƻʬ ʹɑǛʑǝflbȥ̸bDžʛʓjpĤʏˉ˦NJŀlȝk f cĎibˋ˙Ɣʚɸǔf˕ˑŊlʂvĻbțȧɉͪ̃ ʼŧŴØãÏ æ¶ŏɾb+ ˉ˦b ˉ˦lɚɨugr lžŦt g c}bDžʛʓjp + ˉ˦ĤʏŗǗ̟Ʃw˴ƷDzœ~ ŠƚtgglbɐʘǛjͥƭǛDžʛʓ{|ɸƚ˴ƷDzĉlȷ ıtr b{DzœlʒǤLjǪ͓̌NJŀȦwŜ˧Ǜlf žŦtg
(99) cu}lbDžʛʓjgĤʏˉ˦j˴ƷDzĉ ʒǤ۩ŸÚ̔ȝ͓̌f ˟ic ͈Ŕ
(100) Ƽ͞jpòʗj¡ÂÎæǛʛ˯ɬ͟wʣʲˍȮbʒǤÛ ©Å¸Úlȝktb{ŽȻdʮ΄IJƑȼʚɑʖ́lʣʲ͝ʘ tgcòʗ # +8
(101) ˉ˦ˌ̲ɖǛŊɸǔ ubçȗb¡ÂÎæǛ ʛ˯ɬ ŸĤʏǗʹąhʑǝf ˟igcukulbȥ̸b òʗj¡ÂÎæǛʛ˯ɬíʑǝjg ŸĤʏǗʹ͟ëw³£Â© £äb+8
(102) ˉ˦ʆȬ³£Â©£äʃʂlʤ̞tjbòʗ ¡ÂÎæǛʛ ˯ɬħ̿³£Â©£äʃʂlʂvgr lȝk }cu}lb N.
(103) rʑǝƤwɑʖņȮšèty}bíʑǝ͞ĤʏŗǗ ͊gȝʤub{|ĤʏŗǗƤǗwɑʖɓʤʴwr lǖ ̌fcrƤubDžʛʓ + ˉ˦³Ð¹¿ÂlʒǤLjǪ͟ëug kêȝʑǝf
(104) c
(105) ȦłĀ̡ ub̃ɜįŵűƑlɐʘ ǛDžʛʓ͟ëug ˟ig č͓̃ɜįŵűƑ
(106) f ÂãäÍälbˋ˙Ȅĝj{ǍːnɬʓɖǛŊtr lw ʥtg lb˶Ũɝgr ÂãäÍä˕ˑŊĔ̈́tyɸǛ ȦubtrÂãäÍäɐʘǛDžʛʓǝˠ˕ˑŊʥu}ˤjg èȜugr lžŦtg c {rȪʣʲbÏãæ³£ÂÛÂàæj A)+') ɓʄgòʗ ¡ ÂÎæǛʛ˯ɬǝˠjpĦ̳Ǜjʛ˯ʒƅ͏Ĥʏˉ˦IJƹ³£ ©£äͨǛˉ˦¼äḘ̈j =)% âÓáȷ̘ub{|ʑǝ͓ ̌³£Â©£äʃʂugˉ˦Šƚ̜}ctb{|ʒǤ LjǪ͟ëugˉ˦͊gȝkw}bíʑǝʛ˯Ĥʏˉ˦j ̃ɜîǒʀǛˉ˦Ɋ̶ȷ̘u}cɂgbDžʛʓȷ̘w}Ȗ} ؤ·ÜÁáȺʾubÂ×£»Ûßæº. ̪˻u}Ⱦɹˉ˦̟Ʃ. u}ؤ·DžʛʓÜÁálÌÂɐʘǛDžʛʓ̸gʒǤʥwkȷ̘ubw bȪؤ·ÜÁáÌÂʒǤÜÁá uǢ˞ȷ̘u}cçȗbɽŶb Ȧņɑʖ́lƓŶuggʬʑǝfɐʘǛDžʛʓjgbȖ}ɑ ʖ́ u˟igDzÂãäÍä́f½ÍªÂßäȪؤ·ÜÁá ljͺČyȷ̘u}c . . FE.
(107) ʶ
(108) ʵ òʗʒƅ͏jp #
(109) j # ͨǛˉ˦gȷ̘
(110) ˔̖ ƨƻǛòʗȦʒɼl˃ Αʭǁþ̆ʚǥǛʛ˯ʑǝfbʀƁ͍Ąʚ ̌űb̆ʛˉ˦jĤʏˉ˦̢ʽʌƻbȻďˆlˋŞt ʂv̊Şʚʑǝf
(111) c͈Ŕ
(112) Ƽ͞ʣʲbòʗʒǤ + ˉ˦ ̱űw¯ß¾È³£ÂjĤʏˉ˦̢ʽʌƻʑǝfr lȝk }cLJĴ DE=?B>53B?C9C613D?B1<@81Β+% QΓ 9>D5B65B?>WS Β %SΓʃʂw +8
(113) ˉ˦͟ël˟ig}lbʣʲ̈́Ưągɬ ʓ̟ƩǛ³£Â©£äʃʂug +8
(114) ˉ˦j +3
(115) ˉ˦NJŀɔʜl ͰgcȾɹˉ˦ʃʂt} # òʗʒƅ͏jg +8
(116) ˉ˦ʂƓ ƂɈĔw cĦ°ÈÚ͂͟ʣʲ͍ĄƑʣʲ +% Qǟ žĄ͉ˌ̲ # +8
(117) ˉ˦ˌ̲͍ĄƑlòʗ͂͟wr lȝkt g
(118) còʗʒǤLjǪjgbrɬʓ̟ƩǛ³£Â©£ä͓̌Ǜ ˳ƾDz +% QDzĉbDz # @ #
(119) @ DzĉbDz #
(120) Dzĉ IJƑȼʚ́ʄg}ɑʖǪŃɼ̿uʤk} crhb¤·À«Æ ØÐ # @ #
(121) @ ƤwÌŸÜÈãæÄáDzĉĦ̳Ǜòʗ ɑʖ́fb+8
(122) ˉ˦j +8
(123) ˉ˦ŗǗɸʌʚǰķw. . r kb. Ͷƻġ}ɑʖņȮʥuglbƇnǝˠjgȐʺǬʒƅ͏lɇ Ɠwr lʡjbƗɑwǝˠĦĉ ΑȨɤf
(124) cçȗb rhIJƑȼʚ́ɑʖǍǸːʚƓŶwdzDzǛʒƅ͏͟wʣ ʲ~ƫnb{dzDzǛgțǚœű̔ȝlǖ̌fc. FF.
(125) . # ʛ˯ˋ˙jgˉ˦ƆʒœĉkǣȰ͢ǐȄĝˋ˙īʂ. jĖǑ͓̌NJŀȮ}ug #
(126) ³£Â©£äÏ Ùàæç fb+8
(127) ˉ˦kʃʂt c}b # +8
(128) ˉ˦x +8 ˉ˦j +3 ˉ˦kʃʂtb #
(129) ʃʂąxIJɒtr lž Ŧtg c # ʛ˯¯ß¾È³£Âbˡˉ˦b˥̆ʛˉ˦ ʘɽug #a ŚƟĉΒ # )Γûu C97>1<DB1>C4E35B1>413D9F1D?B ?6DB1>C3B9@D9?>
(130) Β*++
(131) ΓɖǛŊwr ċʄwc # ) ħ̿ #
(132) ŚƟĉ ͚Β #
(133) )Γ # ŚƟĉ
(134) ͚Β # )
(135) ΓkÒ Àãõ͔ĉŚƟĉfcçȗb # ́̃ˉ˦ɖǛŊtyr lžŦt g lb # ) lĤʏˉ˦ʘɽugkŢkêȝf c # üb # j # # )
(136) ˍŞŜ˧f c # j # # ŠȻ #
(137) ³£Â©£äÏ Ùàæfb # ħ # ) ûu¯ß¾È³£ÂIJŊ̢ʽ͟gck # #
(138) ħ¯ß¾È³£ÂIJŊǰķubƂɈj͇Ň˧÷̈́tybòʗɸ ǔʚˋ˙ƔʚƅŊfêĦ̓Ŋąh̭̓ˢŒΒ͙̓ŊʓΓ̆ʛˢŒj ʟʛñ͏èȗʳı}w
(139) c # Ͷʒƅ͏Ɋuòʗʒ ƅ͏jgʃʂl÷̈́ujbRÁ¢Ï¥äµä ##b*
(140) b*
(141) Dz˼ÔѾÃʃʂĔ̈́wr bʛ˯ʂĉ͢ǐɀȺDz˼ċ ʄjǧ͓NJŀȮ}ug c ÌÂòʗòʗȻʛ˯ɬʓؤ·ÜÁájgbƌîɾbST+ ˉ˦b # ˴ɱĤʏ͟ëwˉ˦ #
(142) j # ʃʂˉ˦ u˟i jb{ˉ˦lʒǤLjǪƠëwr lȝk g ʛ˯ˋ˙jgØ·Âˉ˦̆ʛ ˍŞˋ˙͞ƓŶug. . . cĎib. lbȥ̸b. òʗʒƅ͏jgØ·Âˉ˦l #
(143) ʃʂwr lžŦ tgc tbòʗʒƅ͏Ø·Âˉ˦ #
(144) ~pn #b+% WQb %Sʃ ʂwr lžŦtg
(145) cüb¡âá¬æʑǝjgØ·Âˉ˦ FG.
(146) # #
(147) ŸĤʏǗʹ͟³£Â©£äʃʂwr lʡ jbØ·Âˉ˦Ȼd³£Â©£äʃʂwr ɬʓąhʑǝ ʒǤLjǪ͟ëugcçȗbØ·Âˉ˦̆ʛˋ˙Ē̋ƤuʱȸʚĖ Ǒ͟gr lžŦ tjbwbòʗjgØ·Âˉ ˦lʒǤLjǪ͟ëugkb}ʛ˯ˋ˙ĖǑ͟gkêȝ fc #
(148) # ɬʓ̟ƩǛ³£Â©£äl + ˉ˦j˴ɱĤʏˉ ˦ȻdĤʏˉ˦kʃʂtgr lžŦtglbòʗʒǤ LjǪ͟³£Â©£äʃʂˉ˦gȝʤjxbțǚ̔ȝ lɏc òʗʛ˯ˋ˙Ĥʏˉ˦ʄg}Ƈnʣʲb{ɀ˧̛đʛ˯ȷĉ ˋ˙Ɣʚ̔ȭfgǼřǍbȐ̓͞żΆȧ͞ˌ̔ȭwȗɓ̄ gc}b³£Â©£äʃʂ @8?B2?<
(149) =IB9CD1D5
(150) 135D1D5Β'$Γj 9?>?=I39> ?>?'$ ?>?DžķʚɖǛŊu}ɹǤɢƚtg c{}bʂĉĪjpˉ˦ȪȬ̆ɽŸj³£Â©£äʃʂ˧ʤ ̞wr lųʹfc{rȪʵbǫdlȖ̏͝ʘu}ʛ˯ˋ˙k ŏˉ˦ə͆ɜ̢ȑu}ǍbżΆĸɩńixbȰ˹åŵƚ Ƞ͞ÿĪ̄ hǭɓʄg}cȪǭɓbǎȬɓɊubʂĉĪ̸gɹǤ³£Â ©£äʃʂˉ˦ŠƚlŜ˧fr kbȪʣʲ 5HF9F? jgÏã æ³£ÂÛÂàæ A)+') ʄgbòʗʒǤjpˉ˦ɸǛ̔ȭ³£ ©£ä¼äḘ̈j =)% ʘɽȷ̘u}c . . FH.
(151) ƛΈȫȔjȗɓ
(152) ʛ˯ȷĉ ʛ˯ȷĉǼř
(153) ɅÿèfǝˠƤ̩ ubĦǝˠjěƻˠk £äϧæÚñä¹äÂǏ}èʣʲ̄ͅu}c}bʛ˯ȷĉΒ ==H==ΓǼřjʣʲčʄ
(154)
(155) ùk >CD9DED9?>1<)5F95G ?1B4 kǯ̞ébǝˠ
(156) ùʒƅ͏}Ͷʒƅ͏k
(157) e ʺǬǼřu }Β'B?D?3?<>E=25B >>?F5B45B= b >>?F5B45B=B5C51B38b(E5253b 1>141c ƛΈȗɓj̜́
(158) ¤·À«ÆØÐʄg}ʣʲ̗ʈ Ȫʣʲ
(159) ɅÿèǝˠjěƻˠƤ̩ū}c¤·À«ÆØÐ } =7 }
(160) ̓ͫ͞DZëubȧ͞îǘĽ͈ǁȚģ LJ}ɑʖņȮljͺŖwôͼ͎p}c}bôĻǘĽ čʄîɃu}Β+12<5
(161) Γ. FI.
(162) +12<5
(163) *E==1BI?645=?7B1@89341D1 DB51D=5>DG9D8ECD5;9>E=12?B =7
(164) G55;C ÌÂʛ˯ˋ˙kˉ˦ŏͳ ǝˠjěƻˠkǼřt}ʛ˯ˋ˙ȷĉ == H == Ǽřk IJÿĪİɿ͝Ǝu}cʛ˯ȷĉ̀k ijIJpbE<2533?C =?496954517<5=549E=$ $ɧƐ#965+538>?<?795C >3 bEB<9>7D?>b &>D1B9?b1>141î 75>D<5$*9CC?391D?B$9<D5>I99?D538b5B79C38 <142138b 5B=1>Iʄg}ɀȴʚIJͳːmb =7 =< #925B1C5)?385b FJ.
(165) $1>>859=b 5B=1>I Lb
(166) Ƞ͐͞ˆİɿȘu}crİɿ Ű ˚̹ubÏ¢á¼æ̿u}ǍÂàËäÐáæčʄuˉ˦ȐȐi}c # - K 9H12<5AE15145<<*D19>"9Db6?B >=5H39D1D9?> $?<53E<1B'B?25CKb#965+538>?<?795C >3 Ȱ˹u}ˉ˦Ì 7 } 1>D98E=1> 2<?3;5B*+ $ ##+538>?<?795C\ Lb
(167) IJ͞ żΆǍbˉ˦̆ͷDzœȰ˹ L IJ̄͞}cˉ˦ŵƚu}Ǎ͈̾İ ɿȘubˉ˦Ī³£Â©£äȰ˹ L IJ̄͞}cčʄu}Dzĉ +12<5 ʥu} jfc+12<5 $0(. 256. . . .
(168)
(169) &,6 &,6 . ;= &< / &< / ,1($*(2&.6$,/
(170) &< /
(171) . 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275( 275(. ,526:3(&21642/ * * *% * * *%. 275( 275( 275( 275( 275( 275(. 70$1* & %/2&.. 275(. /21(. 9',/76,21. #" #" #" #
(172) !
(173)
(174) +/ #"
(175) #". . . 9
(176) 9
(177) 9
(178) 9 9
(179) 9 9 9
(180) 9 9 9 9
(181) 9 9
(182) 9
(183) 9 9
(184) 9 9
(185) 9
(186) 9 9. /(9$/724 : (4 /(9$/724 (4 :
(187)
(188) 4,//$168,2/(6
(189) (4 :
(190)
(191) : : $&,),&%/7( (4 /(9$/724 /(9$/724 $&,),&%/7( /(9$/724 (4 " ". 9 9. 9
(192) 9 9
(193) 9. /(9$/724 : " (4 (4 . 9. +12<5 )5175>DCEC549>6<?G3ID?=5DBI . FK. 21-7*$6,21. $17)$&674( ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' ,2/(*(1' !:56(05 !:56(05 !:56(05 !:56(05 (,25&,(1&( (&621,&.,1521 $%5,26(&+12/2*:. ,2/(*(1' ,2/(*(1' ,2/(*(1' !:56(05 !:56(05 !:56(05. !6(0(//. .
(194) A)+') ʛ˯ˋ˙ȷĉʠȠĮubñȵjñ͗ʄg®¡Å¶ä£»µ¡Ç æÂÊ¿Ï æîÕܶģ¸u}c)% ¦¼Èæáʄgɧıub(9175> 92B?EC=9>93?<E=>C(9175>b+?B?>D?b&>D1B9?b1>141ʄgǴıu}c (9175> Ȉċǭͽǎ (E1>D9D53D)5F5BC5+B1>C3B9@D9?>;9D ʄgǴı u} )% 3% ̴Ĭu}c͍ĄƑʘɽA')EC9>7 1CD)51<+9=5 ')*ICD5=@@<9549?CICD5=C#965+538>?<?795C >3 čʄuɢƚu}c A)+')ʄg} D1A=1>@B?25 @@<9549?CICD5=C#965+538>?<?795C ̮ ĥub͍ĄƑʘɽ P+ɓʄgƚ͔Ŋubɤ·«æÎä®͍ĄƑ u 8E=1>139493B92?C?=1<@B?D59>8)' + + + + b + + + + + )b $+++++++ + +$)@B?25 >D57B1D54%+538>?<?795Cb+?B?>D?b&>D1B9?b1>141čʄu} c ˉ˦LjǤƔʚȷ̘ 3"9D 3U). . Ø·Âˉ˦j + ˉ˦́̃ ˉ˦îk . *B91\^53D?>93;9>C?>b$9CC9CC1E71b&>D1B9?b1>141ʄgŏ ͳu}cŏͳu}ˉ˦ D8545@1BD=5>D?6 5=1D?<?7Ib ,$ jgߣÂȰ ˹u}Ǎ *D1D*@9>\ID? E75\ '5BC?>1<ID?35>DB96E75 9C85B *395>D9693b&D1GG1b&>D1B9?b1>141ʄgȼȪċǪu}c . FL.
(195) (E1>D9 5>5K <?G)% ̔ȭ . #
(196) b # j R =93B?7<?2E<9> ÌÂ =)%ȷı (E1>D9 5>5K <?G. )%1CC1I66I=5DB9H >3 *1>D1<1B1bb,*ʄgȈċǭͽȤǎ ƛȘu}c #
(197) ΒDI@5
(198) Γ # ΒDI@5
(199) ΓbR =93B?7<?2E<9>ΒDI@5
(200) jΓ 8E=1>=)%ƤwÑãæÐ 66I=5DB9H k̮ĥu}c³£Â ©£äʘɽ D85ID?69H ID?@5B=\ 9H1D9?> '5B=5129<9J1D9?>*?<ED9?> "9D53D?>93;9>C?>čʄu * ̔ȭ̄}c *̔ȭ *̔ȭ 6?BG1B4C31DD5B * C945C31DD5B**ŏçˉ˦°æ Âkp}ǍʂƓuǵ̃ ͨǛΒΓˉ˦Ƥ̩ u}cˉ˦ *B91\^53D?>93;9>C?>j \#*)^53D?>93;9>C?> ʄgɢƚub *5H@B5CC6<?G3ID?=5DBI1>1<IC9CC?6DG1B5 ̔ȭu}c ˏ̗Ɣʚ̔ȭ ̔ȭ B1@8'14'B9C=F5BC9?> B1@8'14*?6DG1B5b#1!?<<1bb,* čʄub@19B54*DE45>DYCDD5CDC}.9<3?H?>@19B54D5CDC ƛȘ u}c%?>@19B5441D1 $1>>.89D>5ID5CDC}E>@19B54*DE45>DYCD D5CDCG9D8.5<383?BB53D9?> ʄg}c' ȦǢƶf ĵƚu}c. FM.
(201) ƛΈǪ˗
(202) òʗʒƅ͏kŰŘu}ʛ˯Ĥʏˉ˦ɸǔ òʗʒƅȷĉkŰŘu}ʛ˯Ĥʏˉ˦jp #
(203) j # ʃʂ Šƚw}bȖ}͝ʘu} '$ ?>? ĸɩńigǭɓʄg}c wbƪijɶ== ĻǍʛ˯ˋ˙kÏãæ³£ÂÛÂàæɓ̔ȭw ōIJˉ˦ȐǏôǪŃu 97
(204) j
(205) bʒƅ͏Ͷʒƅ ͏ɊuȦǢˉ˦ɚɨl} 97
(206) cçȗbˉ˦Ƥ̩̔ȭ ̄gbòʗǝˠʛ˯jg #
(207) j # ͨǛˉ˦ʤ̞u} 97
(208) c. FN.
(209) Fig. 1 Distribution of immune cells in skin cell suspensions freshly isolated from skin biopsies of psoriatic patients. Biopsies were performed onplaques of lesional skin (L = 22 patients) and non lesional skin (NL = 7 patients) of psoriatic patients. A, Gating strategy on Aqua/live dead negative cells in relation to cell size (FSC); on viable CD45+ hematopoietic cells (right panel). B, CD45+ cells (%). C, Intracytoplasmic staining of lesional skin cell suspensions using anti–IL-22 mAb, anti–IL-17A mAb, or isotype-matched control mAb after gating on CD45+ cells. C: ****P < 0.0001 by unpaired t test (Mann-Whitney).. GE.
(210) òʗʒƅ͏jp #
(211) j # ͨǛˉ˦ Ļʽʥu}hbòʗʒƅ͏ #
(212) j # ͨǛˉ˦lɚɨu g}cɂgbrͨǛˉ˦jp³£Â©£äʃʂ̢}b #
(213) j # ͨǛˉ˦Šƚ̜}c{ˍȮbʒƅ͏ # ͨǛf 3"9Dˉ˦ #
(214) ͨǛf 3"9Dˉ˦Ͱʱl} 97 cƈ͏IJ³£Â©£ä{|ˉ˦ĪƭŶugr ȝk } 97 c. . GF.
(215) Fig. 2 c-Kit+ cells are major IL-22 producers, and CD3+ T cells are the main source of IL-17 in psoriatic plaques. A, IL-22 and IL-17 expression gated on c-Kit+ CD3- and c-Kit- CD3+ cells; %CD3+ versus c-Kit+ IL-22+/IL-17+ CD45+ cells. B, Cell-surface versus intracytoplasmic staining with anti–IL-22 or anti–IL-17 mAb in relation to c-Kit expression after gating on CD45+ cells. A: Data show 1 representative experiment of 5. **P < 0.01 and ****P < 0.0001 by unpaired t test (Mann-Whitney). . . GG.
(216) Ø·Âˉ˦jgͨǛf³£Â©£äȷ̘ ɂgb3"9D 3U)]ˉ˦j 3"9D 3U)]ˉ˦LjǤȷ̘ w}brˉ˦ŏͳǍb̔ȭu}c{ˍȮb3"9D 3U)]ˉ ˦Ø·Âˉ˦fbï̌ # ͨǛˉ˦fr ʤ̞u}Β 97 Γc tbØ·Âˉ˦ #
(217) ͨǛńib #
(218) ŚƟĉΒ #
(219) )Γʘɽug r lȝk }Β 97 jΓcçȗbï #
(220) ͨǛˉ˦ u + ˉ˦̎ıu}Β 97 Γc. GH.
(221) Fig. 3 Mast cells (c-kit+ FcεRI+ cells) produce IL-22 and IL-17 and express IL-17R in psoriatic plaques. A, Morphology of fluorescence-activated cell sorting–sorted c-Kit+ FcεRI+ mast cells and c-Kit- FcεRI- CD3+ T cells after gating on CD45+ hematopoietic viable cells. B, IL17RA and c-Kit cell-surface expression after gating on c-Kit+ FcεRI+ mast cells and cKit- FcεRI- CD3+ T cells. C, Intracytoplasmic IL-22 and IL-17 production in relation to CD127 expression after gating on c-Kit+ FcεRI+ mast cells. . . GI.
(222) Ø·Âˉ˦ + ˉ˦jp # j #
(223) =)% ƚ͔̔ȭ Ø·Âˉ˦jp #
(224) j # ʘɽʤk}b9>C9DE 8I2B949J1D9?> Ïãæ³£ÂÛÂàæˋŞy} (E1>D9 5>5K <?G)% ɓ ʄgb # #
(225) =)% ʘɽŏçˉ˦âÓáȷ̘u}c{ˍȮbØ ·Âˉ˦ +ˉ˦ ŠȻ # #
(226) =)% ʘɽʥu}Β 97 Γc. . Fig. 4 Quantification of IL-22 and IL-17 mRNA expression at the single-cell level in human mast cells and T cells in skin biopsy specimens of patients with psoriasis. β2-Microglobulin, IL-22, and IL-17 mRNA expression after gating on mast cells (cKit+ FcεRI+ CD3-) and T cells (c-Kit- FcεRI- CD3+) in human psoriatic skin biopsy specimens. . GJ.
(227) ¤·À«ÆØÐdzDzǛʒƅ͏ ɑʖĻʒƅ͏jp +8
(228) ˉ˦͂͟³£ ©£äʘɽ ¤·À«ÆØÐ # @ #
(229) @ ƤwÜÈãæÄáDzĉfò ʗɑʖ́fcr¤·À«ÆØÐdzDzǛʥu}ʒƅ͏ ɑʖĻʒƅ ͏jp #
(230) b # b # b #a b # j RÁ¢Ï¥äµä Β8 Γ =)% ʘɽͶʒƅ͏ Ɋ̶u}c{ˍȮbͶʒƅ͏Ɋuʒƅ͏ #
(231) b #a j RÁ¢Ï¥äµä =)% ʘɽlbɑʖĻ ŠȻdzDzǛ ʒƅ͏jgƂńug}c #a ɑʖĻèȜug}Ƥub #a ɑʖǍèȜug}Β 97 Γc. Fig. 5 Psoriatic plaques that persist despite ustekinumab treatment maintain a gene expression associated with Th17 comparable to untreated plaques. qRT-PCR comparing lesional versus non-lesional skin in both untreated and ustekinumab-treated patients with moderate-to-severe psoriatic plaques was performed. Normal skin from control subjects without psoriasis was also included. NS: normal skin, NL: non-lesional skin, Plaque: lesional skin. *P < 0.05 and **P < 0.01 by paired Student’s t-test. GK.
(232) ¤·À«ÆØÐdzDzǛʒƅ͏jp #
(233) ͨǛˉ˦ Ļʽjgb¤·À«ÆØÐɑʖǍkkxͶʒƅ͏ɊuȦǢΌ g #
(234) =)% ʘɽlʤ̞t}}b¤·À«ÆØÐdzDzǛʒƅ͏jp #
(235) ͨǛˉ˦Šƚ̜}cdzDzǛʒƅ͏jp #
(236) ͨǛ + ˉ˦ŀŞɑ ʖĻ Šʭǁf}lΒ 97 j ΓbΉnmr Ͷ + ˉ˦jp #
(237) ͨǛɼlɑʖĻƂńug}Β 97 j Γc. Fig. 6 CD3-IL-17+ cells are increased in the refractory plaques of ustekinumabtreated patients. Leukocytes were isolated immediately ex-vivo from psoriatic plaques in untreated (n=9) vs. ustekinumab-treated (n = 8) patients. A, Expression of IL-17A (below panel) and isotype control (upper panel) in relation to CD3 expression. B, Persistence of IL17+ CD3+ T cells in plaques from treated patients. C, Significant increase in the percentage of IL-17+ CD3- CD45+ cells in ustekinumab-treated patients. **P < 0.01 by unpaired t test (Mann-Whitney).. GL.
(238) ˟ƣ ȪʵòʗʒǤLjǪ͓̌NJŀȮ}ug #
(239) j # ͨ Ǜˉ˦Šƚu}ctb¤·À«ÆØÐɑʖǍjgǸːʚƓŶw dzDzǛʒƅ͏³£Â©£äʘɽjʃʂȷıwʜʚbÏãæ³£ÂÛ Âàæj A)+') ɓʄgʛ˯ʒƅ͏³£Â©£ä¼äḘ̈ =)% âÓáȷ̘u}c . # òʗǝˠʛ˯ʒƅ͏̃îęlèȜujb̃îę ʑǝ͓. ʓǁʞ͟lfr lʥtg. . còʗjpç˷ʚȹǘ ub. # ï +8
(240) ˉ˦b+8 ˉ˦b+3 ˉ˦j # ³Ð¹¿Âf # ʃʂt ˟ig cukulbȪʣʲbò ʗʒƅ͏jgØ·Âˉ˦l # ͨǛfr ŠƚubØ·Âˉ˦lȖ } # ʃʂˉ˦fŜ˧Ǜʥu}cØ·Âˉ˦ 3"9D 3U)]ˉ ˦ uȷıub¼äḘ̈j =)% âÓáėdØ·Âˉ˦l # ʘ ɽugr lȝk }cĸɩńir ǒʀǛ + ˉ˦l #
(241) j # Όʘɽwr ʡglbˉ˦żΆyxbʛ˯ȷĉǼ řk IJÿĪİɿ͝Ǝub'$ ?>? ĸɩńix Ƞ͞ÿĪˉ ˦ŵƚwȗɓʄgr bòʗʒƅ͏jg + ˉ˦Ø·Âˉ˦ l # ͓̌ďˎɥfr lʥŭt}c . #
(242) Ƽ #
(243) B5<1D54+35<<45B9F549>4E392<5613D?B #+ . užŦt}³£Â©£äf c # $=1CD35<<<9>5 k #+ =)% ʘɽl̟Ʃtr lȝk g cØ·Âˉ˦ʛ˯ jpğm # ʃʂ~pnƇƱ}jbͶƻ̊Ͳfc ¡âá¬æʑǝȠjgbØ·Âˉ˦͓̌¦Ï¥¼æˉ˦f ˟i glbòʗʒƅ͏jğʛ̸gʟʛØ·Âˉ˦Ƃńlž GM.
(244) Ŧtg còʗȻʒƅťw¯ÐÇáɽ̩òʗǝˠͶʒƅ ͏ʛ˯ĸɩlńr ʛʐʂvr lžŦtg lbØ·Â ˉ˦țȧͰʱ ͂͟lfr ʡg cu}lbòʗjg bØ·Âˉ˦͓̌¦Ï¥¼æˉ˦f ǿƣtc # ¯ß¾ ȳ£ÂDz˼ÔѾÃʃʂ̟Ʃuʛ˯͢ǐɀȺ͟lbçȗb òʗɸǔf̆ʛˢŒǃm̱rw
(245) cȪʣʲØ·Âˉ˦l # ʃʂˉ˦fŜ˧Ǜʥu}lb9>F9DB?jgØ·Âˉ˦ ɖǛŊ + ˉ˦ Ǿ̕ + ˉ˦ # ʃʂl÷̈́w r lžŦtjbòʗ ʒƅ͏jgŠȻr lžŦtg cukubr + ˉ˦ # ʃʂ÷̈́ǢŨugnb # ͨǛØ·Âˉ˦ + ˉ˦Ǿ̕ lžŦt} ˟icçȗbȪʣʲjg + ˉ˦ # =)%ʘɽ lʤ̞t}lbƛͭb,- ɑʖDz +% QDzĉɑʖʓɹlȊŮt} kkxbʛ˯ + ˉ˦ # =)% ʘɽwr lȝk g . cȪʣʲjgb+ ˉ˦ # ͨǛɼ =)% {ƤuĈk}r. kb¼äḘ̈j =)% ʘɽǖxuƤǗwǖ̌gr lʥŭ tcÿèhbȪȷ̘ # + ˉ˦jØ·Âˉ˦ȷıt }lbʂĉĪjp # ʃʂˉ˦͟u~êȝɭƇnbt ȷ̘lǖ̌fc çȗb #
(246) ³£Â©£äÏ Ùàæ # üb # j # lʡ gc # j # # ŠȻ # )1 ̿u *++ àä͑Ŋûu¯ß¾È³£ÂɖǛŊty }b # ΄Ćċ ʄȦwcƛͭb+ ˉ˦ɖǛŊǗvbØ·Âˉ˦ #
(247) ńi # ʃʂwr lʡjbØ·Âˉ˦r³£Â©£äʃʂw r òʗʒǤƠëugŜ˧Ǜl˟icؤ·ÜÁájp =9AE9=?4 #
(248) DZë̟ƩtòʗȻɬʓ # ĐƓʚflb # ʌƻʘɽòʗȻɬʓ # ɁƊؤ·ÜÁájgʂv GN.
(249) . cbòʗȻɬʓ # ĐƓʚg ˟ibw # ŏ. ĉǥǛʚòʗʒǤLjǪwōIJnb # Ŏ̢uʒǤLjǪ ͟ëug ǿƣtcńibòʗǝˠjp # ¡ä¼²Å·Â ˳ƾʚņȮgžŦ nb˳ƾ̜Έl̄}bȦņǛ l̞xțȧǮijg<9>931<DB91<)579CDB1D9?>%E=25B %+
(250)
(251) r kŠȻr l˟icçȗb # ïɖǛŊt }ŏɾʘɽug lb¤·À«ÆØÐɑʖǍɑʖņȮl˸ƌf} ǝˠɊub˸ƌk}ǝˠ # =)% ʘɽlȦǢΌgr lʡ g cȪʣʲͶʒƅ͏Ɋu¤·À«ÆØÐdzDzǛʒƅ͏jgȦǢ Όk}cè̺hb # j # ħ̿ŚƟĉˍŞw r kbdzDzǛʒƅ͏ʒǤLjǪ # ~pnb # j # lħ ͟ëugŜ˧Ǜlʥŭtc òʗʒǤ # #
(252) ʃʂ͓̌fc¯ß¾È³£Âk ͈Ŀʃʂt}r³£Â©£äĤʏˉ˦̢ʽʌƻǃm̱rwr b̊Ͳɬʓ̟ƩƠëug cȾɹˉ˦ØãÏ æ¶ ʃʂt # +8
(253) ˉ˦òʗʒǤ͓̌ć˛ýpflb Ø·Âˉ˦ #
(254) ʃʂȝʤggĉģDzĉɓb #
(255) ʃʂugˉ˦ç͏lbØ·Âˉ˦ɸǔʚÂàѼæºͨǛfb w #
(256) ͨǛØ·Âˉ˦ƓŶlʥt}
(257) lb #
(258) ) ʘɽug ˉ˦ #
(259) lˍŞu}ɹǤʥu}Ŝ˧Ǜ˟icrƤubȪʣʲ Ïãæ³£ÂÛÂàæɓʄgØ·Âˉ˦jp #
(260) ) ʘɽ~p nb #
(261) =)% ʘɽj¼äḘ̈lͨǛfr ȝku}cw bòʗjgØ·Âˉ˦ +8
(262) ˉ˦ÿƆ #
(263) ʃʂˉ˦fŜ˧Ǜ ʥu}lbʒƅ͏jgï #
(264) ʃʂw + ˉ˦Ɋubʃʂˉ˦ u Ơëǁƪtg ˟icçȗb # òʗjg #
(265) j # ͓̌ʃʂˉ˦ uʡglbȥ̸žŦï # ʃʂ͟ HE.
(266) ëug tg cukub # # ʃʂ 9>F9DB? jg #
(267) j # ĸɩlǖ̌f žŦtjbtȪʣʲ jgbï̌ # ͨǛˉ˦fØ·Âˉ˦ ˉ˦˝î
(268) Αʭǁ ƓŶug}Ƥub Αʭǁ t # òʗjg # ʃʂ wï̌ˉ˦g ˟icɂgbȪʣʲjgòʗIJƑȼʚ ɑʖ́f¤·À«ÆØÐƤudzDzǛʥu}ʒƅ͏jp =)% ʘɽj ³£Â©£äͨǛɼȷ̘u} rbͶʒƅ͏Ɋu # =)% ʘɽ Šʭǁf}cçȗb #
(269) ɑʖĻ Šʭǁ =)% ʘɽj #
(270) ͨǛ + ˉ˦l}übɑʖĻǝˠ˝ɊuͶ + ˉ˦jp #
(271) ͨǛɼlȦǢ Ƃńug}crǪ˗ # ÿƆ #
(272) ʃʂˉ˦ķǐlƭǬ ʚʂvgr ʥŭujbńibØ·Âˉ˦} # ldzDzǛʒ ƅ͏ #
(273) ʃʂ͟ëugŜ˧Ǜʥugcb¤·À«ÆØÐ dzDzǛʒƅ͏Ƥwɑʖjgb˴ɱĤʏˉ˦k #
(274) ʃʂǰķw r ľ͓f ˟ic . #
(275) j # lʞńʚjʞðʚؤ·¯ß¾È³£Â̢ʽʌƻ. ̟Ʃw lb͈ǁ # ʘɽty}Âßä·¶¥Å¿Ø¤·Ĥʏ ˉ˦ɚɨągʛ˯ˢŒl} žŦ t}r kbòʗʒƅ ͏jgbïØ·Âˉ˦ʃʂt} # ͙̓Ŋʓ̆ʛˢŒ͟ ëub # +8
(276) ˉ˦ˌ̲ɖǛŊɬʓ͟ëug ǿƣtcÌÂ ʛ˯ˉ˦ #
(277) n # l¯ß¾È³£Â̢ʽʌƻǃm̱rw ž Ŧ tgr kŠȻr l˟icȪʣʲjgòʗʒƅ ͏̒ƣt}Ø·Âˉ˦ # ͨǛ} # #
(278) ͨǛf}lb #
(279) ɸʌʚͨǛØ·Âˉ˦ƫȐf}cwbòʗʒƅ͏jg + ˉ˦ ~pn # ͨǛØ·Âˉ˦l¯ß¾È³£Â̢ʽʌƻ͟ëug ˟ic. HF.
(280) ÿèbʶ
(281) ʵbòʗʛ˯ʒƅ͏jp #
(282) j # ͨǛˉ˦ ńibòʗɑʖ́f¤·À«ÆØÐƤwdzDzǛʒƅ͏jp³£Â ©£äʘɽȷ̘u}c{ˍȮb3"9D 3U)]ˉ˦ uȷıu}Ø· Âˉ˦lòʗʒƅ͏ï̌. # ͨǛˉ˦fr Ĵȝku}c. tbØ·Âˉ˦l #
(283) ~pnb #
(284) ) ʘɽugr ʥu}c ɂgb¤·À«ÆØÐdzDzǛʒƅ͏Ͷʒƅ͏Ɋub #
(285) b # b # j 8 =)% ʘɽèȜl}cçȗbɑʖĻʒƅ͏Ɋu¤·À« ÆØÐdzDzǛʒƅͶ + ˉ˦jp #a
(286) ͨǛɼlƂńujbdzDzǛʒ ƅLjǪØ·Âˉ˦k #
(287) l͟ëugŜ˧Ǜlʥŭt}c . . HG.
(288) ʶ ʵ ¡ÂÎæǛʛ˯ɬʒƅ͏jp #a j #a
(289) ͨǛˉ˦g ȷ̘
(290) ˔̖ ¡ÂÎæǛʛ˯ɬ}òʗ ŠȻ (&# ljͺŖwþ̆ʚɬʓǛʛ˯ ʑǝfb{ʒǤLjǪj̈́Ư͍Ąʚ̌ű ʀƁ̌űl͟ëwr l ʥŭtgc¡ÂÎæǛʛ˯ɬȦʒɼƈù
(291) ΑʭǁbƑď
(292) Αfb¡ÂÎæǛʛ˯ɬĤʏƔʚʒǤ˴ɱĤʏˉ˦jɻǏĤ ʏˉ˦̊Şʚ͟ë}tbʛ˯Êà¡ɀ˧Ĉéɸǔ w
(293) c ʛ˯Êà¡ɀ˧ljͺŖw̌űçϢ߮àäƅʌlǺq c̆ʛjpɎIJĕǸʛ˯ǜƻǛĕè͓̌fbĕɣ ƉɱĕɣűƑl͟ëugcrűƑϢ߮àäʆȬfbtÏ¢ ß®àä̆ʛǜƻǛˑǸw}ǖ̌¯ß¾È³£ÂIJŊ ͟ēl f}b¯ß¾È³£ÂIJŊØæ©æ ǔ͓fc¡ÂÎæǛʛ˯ ɬϢ߮àäƅʌ̭̓ưjgɎIJĕǸųʹwr òɴtybˍȮ uʛ˯lǜƻǛƊhœű
(294) cϢ߮àäƅʌl f¡ÂÎæǛʛ˯ɬǝˠŏ˅ÒáÔ·ǣȰ͓ʓŊwbȻd ǣȰʓƤuà·
(295)
(296) c̆ʛÊà¡ɀ˧ĈéȻd¡âá°ä ĒĥƟȞubˍȮ uʟʛȾɹˉ˦Dzœȁʥˉ˦ĤʏǗʹ ̱ɭ bɻǏĤʏ˂jgɬʓƂǞǃm̱rw.
(297) . cukulb. Ϣ߮àäƅʌ¡ÂÎæǛʛ˯ɬǝˠjg ΑʭǁfbÏ¢ ß®àäɁƊ~p̆ʛÊà¡ɀ˧Ĉé̡ȝmgcƛͭbÏ¢ß. HH.
(298) ®àäɁƊؤ·ɻǏĤʏˉ˦lîǕ ʛ˯ʑǝ}wr lʥt g
(299) c ¡ÂÎæǛʛ˯ɬ +8 ˉ˦ 7 ʃʂˉ˦f̙Ǩ ˉ˦bØ·Âˉ˦ jƌƀŽɾ ŸĤʏǗʹ͟ëwˉ˦ü # l͟ëw
(300) c # #a
(301) ʃʂwr ¡ÂÎæǛʛ˯ɬʒǤLjǪ͟gr lžŦtg
(302) cwb¡ÂÎæǛʛ˯ɬjg #a b #a
(303) D8I=93CDB?=1<<I=@8?@?95D9>Β+*#'Γ
(304) ¯ß¾È³£ÂʆȬ³£Â© £ä # ɖǛŊlʂvgctb # +8 ˉ˦ƌƀŽɾ ŠȻ @B?CD17<1>49> ' ŚƟĉf 385=?1DDB13D1>DB535@D?B 8?=?<?7?EC=?<53E<55H@B5CC54?>+85<@5BDI@5 Β)+ Γʘɽu jbØ·Âˉ˦ʃʂt ' ɖǛŊwcƛͭ rb ʛ˯¡âá°äȡ͵jg )+ µ®ÄáĄ͉lɬʓǛŗǗ͓̌ fr lʥtg
(305)
(306)
(307)
(308) }b)+ ʘɽug ŸĤʏǗʹ͟ë ugˉ˦l¡ÂÎæǛʛ˯ɬjgʒǤLjǪjǧ͓f ˟i cçȗb)+ +8 ˉ˦jpʛ˯ÕæÙä®Øæ©æfb¡ÂÎ æǛʛ˯ɬʒƅ͏Ʉƻʛ˯Ɋu
(309) Ęʭǁ + ˉ˦ɚɨl̎ ctbʒƅ͏jgɖǛŊ + ˉ˦ʃʂt}ɬʓǛŊƔĄ͉ɷ̭ lƂńug
(310)
(311)
(312)
(313)
(314) cî¡ÂÎæǛʛ˯ɬ # j #
(315) lʒǤLj Ǫ͓̌NJŀȮ}ujbħ #)Qûu *++ ɖǛŊw
(316)
(317)
(318) c ƛͭ rb{|³£Â©£äċʄʌlbr¨æÊæß¿Ñ ¯ß¾È³£Â # #
(319) µ®ÄáĄ͉ʞńċʄʥugc {ˍȮbr³£Â©£äϢ߮àäãààäʘɽǰķub ʟʛ±ßæ°äŞǪljͺŖwr lʡg
(320)
(321) c¡ÂÎæǛʛ˯ ɬȩȳ̃ʒƅ͏jgĤʏʌƻlžŦtglb # j #
(322) ȩȳ̃ʒƅ͏ʃʂˉ˦ȝk ggc. HI.
(323) ¡ÂÎæǛʛ˯ɬƤubòʗ +8 ˉ˦ +3 ˉ˦bØ·Âˉ˦b # l #
(324) j # ʘɽ͟ëuj
(325) bɽŶb{|ʑǝƠëw ³£Â©£äƤwDzĉʖɓl̈́gcwbòʗĻ̺ hDz # @ DzĉDz +% QDzĉbDz #
(326) DzĉIJƑȼʚ́lņȮʚ ɑʖ́ uʄggcçȗb¡ÂÎæǛʛ˯ɬ ŸĤʏǗʹ͟ ëw³£Â©£äjµ®ÄáĄ͉¼æ°¿Âu}ɑʖlņȮʚf ˟ijbƛͭb˳ƾʚȦņǛlžŦtg
(327)
(328) cukul b¡ÂÎæǛʛ˯ɬ ŸĤʏǗʹ ghËß½£ÚlƳf czb+8
(329) ˉ˦
(330)
(331) )+ˉ˦³Ð¹¿Âf ƚ˞t
(332) b+8 ˉ˦Øæ©æf )+ ʘɽuggͶ +8 ˉ˦f lb+8
(333) ˉ˦j +8 ˉ˦l¡ÂÎæǛʛ˯ɬǝˠʒƅ͏j̃ɜ ȷıt
(334)
(335)
(336) bçȗbòʗǝˠ #
(337) ʃʂw + ˉ˦lʤ̞t}} f
(338)
(339) crr kb #
(340) # b #
(341) ¡ÂÎæǛʛ˯ɬ ò ʗħ̿ʃʂt³£Â©£äf gi
(342)
(343) c k # òʗ~pn¡ÂÎæǛʛ˯ɬjǧ͓fb͈ Ŀʘɽlʤ̞tg
(344)
(345) c ŸĤʏǗʹ͟ëw³£Â©£äf # j #
(346) # ¯ß¾È³£Â̢ʽʌƻ͟ëujb ¯ß¾È³£ÂIJŊDz˼ÔÑ¾ÃŞǪǰķw
(347)
(348)
(349)
(350)
(351)
(352)
(353) r lʡgcĻʵʥu}hòʗ # ʃʂØ·Âˉ˦lƠëu g}lb¡ÂÎæǛʛ˯ɬjgŠȻfkêȝfcçȗb¡Â ÎæǛʛ˯ɬbØ·Âˉ˦ #
(354) ǰķwr +8 ˉ˦ġćĔu.
(355) . b. ˉ˦Ǫɳ 7 ʃʂ͓̌fr lȝk gcńibØ· Âˉ˦̟Ʃt}ɬʓǛÛÁ¢¦æ¼æ¯ß¾È³£Âk³£Â ©£äʃʂĔ̈́wr ȝk g
(356)
(357) cwbØ·Âˉ˦ ¡ÂÎæǛʛ˯ɬʂvgɬʓŗǗjǧ͓ˉ˦f ˟ic }bØ·Âˉ˦ǚǛȧͰʱglbǥǛʒƅ͏Ƃńl HJ.
(358)
(359)
(360) bØ·Âˉ˦˪ʿ̟ǃt +8 ˉ˦ɖǛŊjɚɨʔ ą}ȀɵÊà¡ɀ˧Ĉéǵnr lžŦtj
(361) bØ·Â ˉ˦ʒǤˑǸ͟g ˟ic ȪʣʲÏãæ³£ÂÛÂàæɓʄgb¡ÂÎæǛʛ˯ɬǝˠjp ǒʀǛ ŸĤʏǗʹ͟ëwˉ˦bʛ˯ƭŶug ŸĤʏǗʹ ͟ëwˉ˦IJƹ # } #
(362) ͨǛˉ˦òʗǝˠ Ɋ̶wr bíʑǝʒǤjpƭǬʚjĦ̳ʚʒǤʞ͊ȷ̘u}c . . HK.
(363) ƛΈȫȔjȗɓ
(364) ʛ˯ȷĉ
(365) ɅÿèfǝˠƤ̩ ubĦǝˠk£äϧæÚñä¹ä Ǐ}èʣʲ̄ͅu}c}bʛ˯ȷĉΒ ==H ==Γj̃ɜΒ =#ΓǼřjʣʲčʄ ùk >CD9DED9?>1<)5F95G?1B4 k ǯ̞ébǝˠ
(366) ùʒƅ͏}Ͷʒƅ͏k
(367) e ʺǬǼřu} Β'B?D?3?<>E=25B >>?F5B45B= b >>?F5B45B=B5C51B38Γc ƛΈȗɓj̜́
(368) ÌÂʛ˯ˋ˙kˉ˦ŏͳ ʶ
(369) ʵ ɦv̄}cčʄu}Dzĉ +12<5 ʥwc. HL.
(370) #/'. 156. # %+6 %+6 .
(371) .
(372)
(373) . %; . . . 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175' 175'. +516:2'%10641. ). 175'. .10'. 9&+.76+10.
(374) !
(375) .
(376)
(377) !
(378)
(379) . ! . 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9. . 10,7)#6+10 .'9#.714 .'9#.714
(380). .'9#.714 : 4+..#068+1.'6
(381) 4+..#068+1.'6 : : '4 : '4 : #%+(+%$.7' . . ". 9. 7/#0). 9. 37#. #07(#%674' +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& +1.')'0& '%610+%-+0510 '%610+%-+0510 '%610+%-+0510 '%610+%-+0510 #$5+16'%*01.1): :56'/5. :56'/5 *'4/1+5*'4. . +12<5)5175>DCEC549>6<?G3ID?=5DBI ÌẪɜîǒʀǛˉ˦ˀ̉ ǒʀǛˉ˦ 1>;CY21<1>354C1<DC?<ED9?>
(382) H*97=1<4B938b.9>CD?> '1B;B &1;F9<<5b&>D1B9?b1>141ƺ͒u}ÒËàä̃k <I=@8?3ID5C5@1B1D9?>=549E=K.9C5>D >3 b*DBE>?b1>141ʄg}ə ͆ơǁ͋ǕɓǏ}c . HM.
(383) żΆĸɩ ɧƐ
(384) Α65D1<31<6C5BE=.9C5>D >3 ńi} )?CG5<<'1B; $5=?B91< >CD9DED5)'$
(385) ɧƐ#965+538>?<?795C >3 ʄg}c B565<49>
(386) V7 =<1<29?385=58B9>7b*1>957?bb,*ƓŶé '$>7 =<*97=1<4B938j ?>? V7 =<1<29?385=58B9>7 Ƞ͞żΆĸɩńi}c ˉ˦LjǤƔʚȷ̘ ʶ
(387) ʵjp ŠȻȼȪċǬ}c *̔ȭ ʶ
(388) ʵjp ŠȻ̔ȭu}c ˏ̗Ɣʚ̔ȭ ʶ
(389) ʵjp ŠȻ̔ȭu}c . . HN.
(390) ƛΈǪ˗ .
(391) ¡ÂÎæǛʛ˯ɬʒƅ͏ɚɨlʥt} + ˉ˦ȷ̘ ¡ÂÎæǛʛ˯ɬʒƅ͏jgˉ˦ɚɨlr bˉ˦IJ ƹgòʗǝˠ Ɋ̶ȷ̘u}c{ˍȮbíʑǝjp + ˉ˦ŀŞ ʞ̞͊k}lΒ 97 j Γb¡ÂÎæǛʛ˯ɬʒƅ͏ +8 ˉ˦ŀŞl˾unΌk}Β 97 ΓcçȗbͶ +8 ˉ˦)+
(392)
(393) + ˉ˦ŀŞĈéwĞšʥu} 97 c. IE.
(394) Fig. 7 Increased infiltration of Th2 cells inlesional skin of AD relative to psoriasis. Single cell suspensions from lesional skin biopsies were prepared from atopic dermatitis (AD; skin= 8) and psoriasis (Pso; skin=10) patients. A, Strategy to gate for CRTH2+ and CRTH2- CD161+ cells on T cells in skin B, % CD3+ T cells. C, % CRTH2+ and % CRTH2- CD161+ gated on CD3+ T cells in skin. Data shown are mean ± SEM. ***P < 0.001 by unpaired Student’s t-test.. IF.
図
+7
関連したドキュメント
variants など検査会社の検査精度を調査した。 10 社中 9 社は胎 児分画について報告し、 10 社中 8 社が 13, 18, 21 トリソミーだ
神奈川県相模原市南区松が枝町17-1 1月0日(土)
このように資本主義経済における競争の作用を二つに分けたうえで， 『資本
第四章では、APNP による OATP2B1 発現抑制における、高分子の関与を示す事を目 的とした。APNP による OATP2B1 発現抑制は OATP2B1 遺伝子の 3’UTR
マーカーによる遺伝子型の矛盾については、プライマーによる特定遺伝子型の選択によって説明す
および皮膚性状の変化がみられる患者においては，コ.. 動性クリーゼ補助診断に利用できると述べている。本 症 例 に お け る ChE/Alb 比 は 入 院 時 に 2.4 と 低 値
（４） 「舶用品に関する海外調査」では、オランダ及びギリシャにおける救命艇の整備の現状に ついて、IMBVbv 社(ロッテルダム)、Benemar 社(アテネ)、Safety
私たちは、私たちの先人たちにより幾世代 にわたって、受け継ぎ、伝え残されてきた伝
